Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

Evaluate the efficacy of a sequential regimen of 14 days in patients with catheter-related bacteremia by S. aureus methicillin-susceptible, selected based on a pre-established clinical and microbiological criteria.

Inclusion Criteria:

• Patients ≥ 18 years with a minimum weight of 40 kg.
• Microbiological Isolation of S. aureus susceptible to meticillin.
• Start antibiotic treatment with drugs active against S. aureus within 72 hours from the onset of clinical manifestations.
• Women of childbearing potential, negative pregnancy test negative serum or urine or statement is not pregnant.
• Prescription prior treatment must be independent and decoupled patient inclusion in the study, corresponding exclusively to clinical practice.

Exclusion Criteria:

• Polymicrobial bacteremia.
• Neutropenic patients.
• Patients addicted to intravenous drugs.
• Patients with malignancies with expected survival less than 6 months.
• Severe allergy to beta-lactams or fluoroquinolones.
• Creatinine clearance <20ml/min.
• Need for hemodialysis, peritoneal dialysis or plasmapheresis.
• Clinical signs of deep infection in the first five days of treatment (mucocutaneous lesions suggestive of IE, embolic events, suppurative thrombophlebitis.
• Predictors of bacteremia complicated:
• Positive blood cultures for 48-96 hours of starting treatment antistaphylococcal
• Clinical Instability
• Signs of sepsis or persistent fever at day 4 of treatment
• Existence of valvular or vascular prosthetic joints, vascular catheter not removed within three days
• Heart disease predisposing to endocarditis.
• Patients presenting diagnosis concomitant infection by another organism.
• Pregnant or breast-feeding.
• Patients with epilepsy.
• Patients with a history of tendon disorders related to fluoroquinolone administration.
• Not have signed informed consent.